Table 4 Summary of adverse events by system organ class
|  | Incidence Rate per 100 Patient-years†| ||
|---|---|---|---|
System Organ Class | Sitagliptin 100 mg | Non-exposed | Difference between Sitagliptin and Non-exposed (95% CI)* |
Blood and Lymphatic System Disorders | 1.1 | 0.6 | 0.4 (0.0, 0.8) |
Cardiac Disorders | 4.2 | 4.3 | -0.2 (-1.1, 0.7) |
Congenital, Familial, and Genetic Disorders | 0.2 | 0.3 | -0.0 (-0.3, 0.2) |
Ear And Labyrinth Disorders | 1.7 | 2.0 | -0.4 (-1.0, 0.2) |
Endocrine Disorders | 0.3 | 0.5 | -0.2 (-0.5, 0.1) |
Eye Disorders | 4.0 | 4.3 | -0.2 (-1.1, 0.6) |
Gastrointestinal Disorders | 26.0 | 27.7 | -1.2 (-3.7, 1.2) |
General Disorders And Administration Site Conditions | 8.8 | 9.3 | -0.6 (-1.9, 0.8) |
Hepatobiliary Disorders | 1.3 | 1.1 | 0.2 (-0.3, 0.7) |
Immune System Disorders | 1.0 | 1.1 | -0.1 (-0.6, 0.3) |
Infections And Infestations | 49.2 | 48.1 | 1.8 (-1.7, 5.3) |
Injury, Poisoning And Procedural Complications | 9.7 | 9.4 | 0.7 (-0.7, 2.1) |
Investigations | 15.1 | 15.7 | -1.2 (-3.0, 0.6) |
Metabolism And Nutrition Disorders | 9.3 | 16.3 | -6.8 (-8.5, -5.2) |
Musculoskeletal And Connective Tissue Disorders | 20.3 | 19.4 | 1.0 (-1.1, 3.0) |
Neoplasms Benign, Malignant And Unspecified | 2.2 | 1.7 | 0.6 (-0.0, 1.2) |
Nervous System Disorders | 15.4 | 15.5 | -0.2 (-2.0, 1.6) |
Pregnancy, Puerperium, and Perinatal Conditions | 0.0 | 0.1 | -0.0** |
Psychiatric Disorders | 4.6 | 4.7 | 0.0 (-0.9, 1.0) |
Renal And Urinary Disorders | 3.0 | 3.0 | -0.1 (-0.8, 0.7) |
Reproductive System And Breast Disorders | 2.8 | 3.2 | -0.3 (-1.1, 0.5) |
Respiratory, Thoracic And Mediastinal Disorders | 8.8 | 8.6 | 0.2 (-1.2, 1.4) |
Skin And Subcutaneous Tissue Disorders | 8.6 | 7.3 | 1.3 (0.1, 2.5) |
Social Circumstances | 0.0 | 0.1 | -0.0** |
Surgical and Medical Procedures | 0.1 | 0.1 | 0.0** |
Vascular Disorders | 5.8 | 5.8 | -0.2 (-1.2, 0.9) |